Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2800MR)

This product GTTS-WQ2800MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2800MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1118MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ5079MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ6476MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ5395MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ8028MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ11269MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ12677MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ10506MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW